In vivo SCIDbeige xenograft model for DLBCL (RL) Combination experiments. (A) The combination of oral AT-101 35 mg/kg per day for 10 days regimen plus intraperitoneal cyclophosphamide (Cy) and intraperitoneal rituximab (R) in four administrations together on days 2, 4, 6, 8 showed significantitumor volume control compared to any other treatment group. (B) The multiple comparison analysis shows the superiority of the triplet combination to each other group (P ≤ .034). Data represent P values for the comparisons. All significance testing was done at the P less than .05 level. N equals 7 in each group (n=6 in control group).